Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024519 | 1.00 | TACR1 (0.61) | TACR1 | |
| SCHEMBL3315691 | 1.00 | TACR1 (0.61) | TACR1 | |
| SCHEMBL5411632 | 0.92 | TACR1 (0.58) | TACR1 | |
| SCHEMBL5409127 | 0.90 | TACR1 (0.53) | TACR1 | |
| SCHEMBL6800492 | 0.90 | TACR1 (0.53) | TACR1 | |
| SCHEMBL3319900 | 0.86 | TACR1 (0.47) | TACR1 | |
| SCHEMBL2487726 | 0.84 | TACR1 (0.54) | TACR1 | |
| SCHEMBL2487727 | 0.84 | TACR1 (0.54) | TACR1 | |
| SCHEMBL13647340 | 0.83 | TACR1 (0.59) | TACR1 | |
| SCHEMBL5411394 | 0.83 | TACR1 (0.46) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012175434-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING VESTIPITANT | GLAXO GROUP LIMITED (GB) | 2012-12-27 | — | — | WO | claimed |
| US-20100317666-A1 | Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss | GLAXO GROUP LIMITED | 2010-12-16 | — | — | US | claimed |
| US-7625904-B2 | Methods for the treatment of sleep disorders | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-01 | — | — | US | claimed |
| CN-101568341-A | Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss | GLAXO GROUP LTD (GB) | 2009-10-28 | — | — | CN | claimed |
| EP-2079470-A2 | COMPOSITION COMPRISING AN NK-1 RECEPTOR ANTAGONIST AND AN SSRI FOR THE TREATMENT OF TINNITUS AND HEARING LOSS | Glaxo Group Limited (GB) | 2009-07-22 | — | — | EP | claimed |
| EP-1460066-B1 | Piperazine compounds as Tachykinins inhibitors | GLAXO GROUP LTD (GB) | 2009-07-01 | — | — | EP | claimed |
| US-20080249108-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | US | claimed |
| EP-1454901-B1 | Pharmaceutical compositions comprising tachykinins antagonists and a serotonin reuptake inhibitor. | GLAXO GROUP LTD (GB) | 2008-09-03 | — | — | EP | claimed |
| CN-100413850-C | Chemical compounds | GLAXO GROUP LTD (GB) | 2008-08-27 | — | — | CN | claimed |
| WO-2008046882-A2 | COMPOSITION COMPRISING AN NK-1 RECEPTOR ANTAGONIST AND AN SSRI FOR THE TREATMENT OF TINNITUS AND HEARING LOSS | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | WO | claimed |
| US-20040157858-A1 | Piperazine derivatives as tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2004-08-12 | — | — | US | claimed |
| EP-1218359-B1 | PIPERAZINE COMPOUNDS AS TACHYKININS ANTAGONISTS | GLAXO GROUP LTD (GB) | 2004-07-07 | — | — | EP | claimed |
| US-20040048862-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2004-03-11 | — | — | US | claimed |
| EP-1377560-A1 | PIPERAZINE DERIVATIVES AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-01-07 | — | — | EP | claimed |
| US-6642240-B2 | Piperazine derivatives; antagonists of tachykinins, including substance P; 2-(4-fluoro-2-methyl-phenyl)piperazine-1-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)methyl amide for example | SMITHKLINE BEECHAM CORPORATION | 2003-11-04 | — | — | US | claimed |
| US-20030028021-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2003-02-06 | — | — | US | claimed |
| CN-1391564-A | Chemical compounds | GLAXO GROUP LTD (GB) | 2003-01-15 | — | — | CN | claimed |
| WO-2002081461-A1 | PIPERAZINE DERIVATIVES AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-10-17 | — | — | WO | claimed |
| EP-1218359-A2 | PIPERAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-07-03 | — | — | EP | claimed |
| WO-2001025219-A2 | PIPERAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2001-04-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030028021-A1 | Chemical compounds | TACR1, TACR2, TAC3 | TACR1 1/4885 |
| US-20040157858-A1 | Piperazine derivatives as tachykinin antagonists | NPSR1, SSTR2, PROKR1 | TACR1 6/4885 |
| US-20040048862-A1 | Chemical compounds | TACR1, TACR2, TAC3 | TACR1 1/4885 |
| US-20080249108-A1 | Chemical Compounds | CYP11B2, CYP11B1, CYP21A2 | TACR1 159/4885 |
| US-20100317666-A1 | Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss | HTR1A, TPH1, HTR5A | TACR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.